Please login to the form below

Not currently logged in
Email:
Password:

EMA publishes drug information format

The European Medicines Agency has published the format in which pharmaceutical companies are to submit information on all medicines registered in the European Union

The European Medicines Agency (EMA) has published the format in which pharmaceutical companies are to submit information on all medicines registered in the European Union (EU).

The latest requirement is part of the agency's pharmacovigilance plans to strengthen systems to monitor the safety of medicines in the EU, and increases transparency and access to information.

Companies will need to submit relevant information outlined in the guidance by July 2, 2012.

The EMA has said the data will enable the creation of a list of all medicines authorised and registered in the EU, both by the EMA and national regulatory bodies.

The plans will also improve the identification of medicines and better co-ordinate their regulation and monitoring, according to the EMA.

Beginning in autumn, companies can organise online and face-to-face sessions with the agency to discuss the requirements. The EMA has also designed a data-entry tool to help small and medium-sized businesses.

The EMA has further information on the new format for information on medicines.

4th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...
Understanding the evolving CAR-T market
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Infographics